Stymied on Nas­daq, Ap­ple Tree’s Brae­burn sinks an­oth­er short putt with late-stage im­plant

Brae­burn Phar­ma­ceu­ti­cals is not out to rev­o­lu­tion­ize ther­a­py for the neu­ro­log­i­cal and psy­chi­atric dis­eases it fo­cus­es on. The Prince­ton, NJ-based biotech has one ap­proved prod­uct …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER